Insiders Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,458 ^JPY	-2.47%		+0.55%	+2.60%

Apr. 18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
Apr. 17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03	CI
Sosei Shareholders Greenlight Name Change, Top Management Appointments	Mar. 28	MT
Sosei Group Changes Names of Company, Subsidiaries	Feb. 16	MT
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer	Jan. 05	CI
Sosei Heptares and Kallyope Nominate First Gpcr Target for Therapeutic Development in Gastrointestinal Diseases	Nov. 10	CI
Sosei Group Corporation Announces Executive Appointments	23-03-23	CI
Sosei Group Corporation Approves Management Changes	22-03-24	CI
Sosei Group Corporation Approves Executive Changes	22-03-24	CI
Sosei Group Corporation Appoints Chris Cargill to the New Role of Group Chief Operating Officer	21-03-24	CI
Sosei Group Corporation Appoints Hironoshin Nomura, as Senior Vice President Investor Relations and Corporate Strategy	20-09-03	CI
Sosei Group Corporation Appoints Rolf Soderstrom as New Board Director and Promotes Dr. Malcolm Weir to Executive Vice Chairman	20-05-13	CI
Sosei Heptares Announces Management Changes	20-03-25	CI
Sosei : Heptares announces nomination of a third clinical candidate by Pfizer from multi-target drug discovery collaboration	19-12-24	AQ
Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-Target Drug Discovery Collaboration	19-12-24	CI
Sosei Group Corporation Announces the Appointment of Mr. Noriaki Nagai as External Director	19-02-28	CI
Sosei Group Corporation Announces Management Changes	18-12-12	CI
Sosei Group Corporation Appoints Chris Cargill as Executive Vice President and Chief Financial Officer	18-11-01	CI
Sosei Group Corporation Announces Executive Changes	18-06-04	CI
Sosei : Notice of Withdrawal of New External Director Nomination	18-06-04	PU
Sosei Group Corporation to Withdraw Nomination of Michael Hayden as A New External Director	18-06-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Insiders

Filters